Section 35(2AB) for Pharma R&D: The DSIR Reconciliation Playbook

A DSIR-approved in-house R&D centre attached to a large Indian pharma company closes its previous year on 31 March with an in-house R&D expenditure book of approximately Rs 850 crore — Rs 620 crore of revenue expenditure covering scientific research staff salaries, consumables and reagents, patent filing costs, and small-scale trial batches at the approved facility, plus Rs 230 crore of capital expenditure covering laboratory equipment installed at the facility. The R&D cost centre general ledger carries a further Rs 90 crore of building-refurbishment cost that management has capitalised under Ind AS 16 but which sits outside Section 35(2AB) because the statutory provision explicitly excludes land and building. The Form 3CL certificate that the company files with DSIR by 31 October must reconcile these four positions — the general-ledger extract, the Ind AS 38 development-phase capitalisation, the DSIR-listed-item filter, and the double-deduction bar — before the Form 3CLA schedule attached to the return of income can carry the weighted deduction into the tax computation. This is the Section 35(2AB) weighted deduction pharma R&D DSIR Form 3CL 3CLA reconciliation cascade at operating scale, and the discipline that keeps the DSIR certificate, the statutory audit position on Ind AS 38 capitalisation, and the deferred tax bridge under Ind AS 12 in synchronised alignment is what separates a clean 100 percent deduction from a scrutiny-stage adjustment under Section 143(3).

Quick reference

The reconciliation in one paragraph

The Section 35(2AB) reconciliation cascade runs from a single source — the R&D cost centre general ledger of the previous year — through four sequential filters before it lands in the Form 3CLA schedule of the income-tax return. Filter one is the DSIR-approved-facility gate: only expenditure incurred at the facility for which a valid Form 3CM approval is on record for the previous year qualifies at all, so the extract is scoped to the plant code or cost centre hierarchy that maps to the approved facility. Filter two is the DSIR-listed-item taxonomy: within the approved-facility scope, revenue expenditure eligible for the deduction is enumerated in the DSIR guideline (scientific staff salaries, consumables, reagents, patent filing fees, small-scale trial batches, collaborative research fees to approved institutions), and capital expenditure eligible for the deduction is enumerated separately (laboratory equipment installed at the facility, instruments, R&D computers) with land and building explicitly excluded. Filter three is the double-deduction bar: any cost that also qualifies for deduction under another chapter is removed from the Section 35(2AB) pool. Filter four is the accounting-standards overlay: Ind AS 38 dictates whether the cost is capitalised as a development-phase intangible in the books, and Ind AS 12 draws the deferred tax bridge across the timing difference between the book carrying amount and the tax revenue-expensed treatment. The Form 3CL year-end certificate reports the certified quantum split by revenue and capital; the Form 3CLA return schedule carries the deduction into the tax computation; the deferred-tax movement flows through the notes to the financial statements and reconciles the current tax and deferred tax lines of the profit-and-loss account.

What the scenario looks like in India

The DSIR-approved in-house R&D model is the operating template for every large integrated Indian pharma group and for a growing subset of speciality API and biosimilar players. The reference persona for this article is a Hyderabad-based R&D centre of the scale of a Dr Reddy’s Bollaram unit — a dedicated R&D building housing formulation development, analytical R&D, biopharmaceutics, intellectual property, and regulatory affairs teams, holding a Form 3CM approval issued by DSIR for the specified block of years, with an annual in-house R&D expenditure book in the mid-to-high hundreds of crore.

The illustrative brand palette that operates DSIR-approved in-house R&D facilities at this scale includes the integrated formulator and API leaders — Sun Pharmaceutical Industries, Dr Reddy’s Laboratories, Cipla, Aurobindo Pharma, Lupin, Zydus Lifesciences (Cadila Healthcare), Torrent Pharmaceuticals, Alkem Laboratories, Glenmark Pharmaceuticals, Cadila Pharmaceuticals — and the biosimilar, speciality, and API specialists — Biocon Biologics (a Biocon subsidiary), Divi’s Laboratories, Piramal Pharma, Ipca Laboratories, Ajanta Pharma, Suven Life Sciences (Suven Pharmaceuticals), Neuland Laboratories, Natco Pharma, Laurus Labs, Granules India, Strides Pharma Science, and JB Chemicals & Pharmaceuticals. R&D facility geography clusters around Hyderabad and Visakhapatnam (Telangana and Andhra Pradesh — Bachupally, Bollaram, IDA Jeedimetla), Ahmedabad and Vadodara (Gujarat — Halol, Sarkhej, Sanand), Mumbai and Thane (Maharashtra — Kalwe, Turbhe), Bengaluru (Karnataka), Chennai (Tamil Nadu), and Goa (Verna) — with the Baddi, Himachal Pradesh cluster still dominant on the manufacturing side but a smaller share of dedicated R&D infrastructure.

The single-facility R&D model is the reconciliation base case. Groups with more than one DSIR-approved facility — a formulation R&D centre in one city and a biologics R&D centre in another, each holding a distinct Form 3CM — run the cascade in parallel and consolidate the certified quantum before the Form 3CLA return schedule is filed at the assessee level. Multi-facility groups typically maintain one Form 3CL per facility and a master reconciliation working paper at the corporate finance level that consolidates the facility-level certificates into the return-level quantum.

The regulatory overlay — Section 35(2AB), DSIR guideline, Ind AS 38 and Ind AS 12

Four regulatory anchors govern the Section 35(2AB) reconciliation surface, and each maps to a specific control point in the year-end close.

Section 35(2AB) of the Income-tax Act 1961 (retained in the Income-tax Act 2025 codification) allows a weighted deduction on in-house scientific research and development expenditure incurred by a company engaged in the business of biotechnology or in the business of manufacture of any article or thing (other than an article specified in the Eleventh Schedule — largely low-priority consumer goods, not relevant to pharma) on an in-house R&D facility approved by the Secretary DSIR. The deduction rate has been reduced twice by the Finance Acts — from 200 percent to 150 percent effective 1 April 2017, and from 150 percent to 100 percent effective 1 April 2020. Assessment year 2021-22 and every year thereafter is a 100 percent deduction, so the amount claimed matches the amount incurred and the “weighting” is no longer a numerical uplift but is retained procedurally as the DSIR-approved pathway.

The DSIR guideline (reference DSIR/Sec35(2AB)/1/2021) sets out the approval framework and the enumerated eligible-cost categories. The company applies for facility approval on Form 3CK, submitting facility details, personnel, R&D programme, and prior-year expenditure. DSIR issues the approval order on Form 3CM for a specified block of years, subject to cyclical review. The company and its statutory auditor jointly sign Form 3CL for each previous year, certifying the quantum of in-house R&D revenue expenditure and capital expenditure eligible for the deduction — Form 3CL must reach DSIR by 31 October following the previous year. The company then attaches Form 3CLA to its income-tax return, disclosing the Section 35(2AB) deduction claimed, the Form 3CM reference and validity period, and the Form 3CL certified quantum. The four documents together — 3CK, 3CM, 3CL, 3CLA — form the linked audit trail that the assessing officer will trace at any scrutiny, and a break in any link is grounds for disallowance.

Ind AS 38, Intangible Assets, governs the book-side treatment of R&D expenditure. Research-phase expenditure is expensed in the profit-or-loss account when incurred; development-phase expenditure is capitalised as an intangible asset when the enterprise can demonstrate the six-condition test — technical feasibility of completing the intangible so that it will be available for use or sale, the intention to complete and to use or sell it, the ability to use or sell it, the manner in which it will generate probable future economic benefits, the availability of adequate technical, financial, and other resources, and the ability to measure reliably the expenditure attributable to the intangible during its development. In pharma, development phase typically commences when a molecule has completed proof-of-concept work, management has committed to advancing it into a specified indication with an identifiable regulatory pathway (Investigational New Drug filing, an ANDA for a generic, a Biologics License Application for a biosimilar), and the expenditure attributable to that programme can be measured reliably. The capitalised intangible is subsequently amortised over its useful life once it becomes available for use.

Ind AS 12, Income Taxes, closes the book-tax loop. Where R&D expenditure is capitalised for book purposes under Ind AS 38 (development-phase intangible) but revenue-expensed for tax under Section 35(2AB), the timing difference gives rise to a deferred tax liability equal to the applicable tax rate times the intangible’s carrying amount at the balance-sheet date. The DTL then unwinds through the profit-and-loss account as the intangible is amortised through cost of sales over its useful life — reversing over the amortisation period and matching the tax charge to the book earnings pattern. The Section 35(2AB) reconciliation therefore does not end at the Form 3CLA return schedule; it continues through the deferred tax note in the annual financial statements.

A worked example — a Hyderabad R&D centre at previous-year close

Illustrative — the following figures represent the operating pattern of a large integrated Indian pharma R&D centre of the scale that DSIR approves for Section 35(2AB). Public disclosures do not report facility-level R&D expenditure at this granularity; cross-verify against your own Form 3CL working paper and R&D cost-centre extract before action.

A Hyderabad-based in-house R&D centre closes the previous year on 31 March with an R&D cost centre general ledger position of Rs 850 crore. The cost-centre extract, before any Section 35(2AB) filter is applied, breaks down as follows.

Filter one — DSIR-approved-facility gate — is passed for all lines that map to the R&D building at the approved Bollaram address; the Rs 12 crore of marketed-product clinical trials is scoped out at this stage because the trials are conducted at hospital sites outside the approved facility.

Filter two — DSIR-listed-item taxonomy — removes the Rs 90 crore building refurbishment (land and building bar under Section 35(2AB)). All other capital lines — laboratory equipment (Rs 158 crore), instruments (Rs 55 crore), R&D computers (Rs 17 crore) — are DSIR-listed capital and pass through. All revenue lines (scientific staff, consumables, patent filings, small-scale trial batches, collaborative research fees, allocated utilities) are DSIR-listed and pass through.

Filter three — double-deduction bar — removes any cost that also qualifies under another chapter. In this illustrative extract, no cost element is double-claimed, so the filter is a no-op for the previous year.

The Form 3CL certified quantum after the three filters is therefore Rs 620 crore of revenue expenditure (Rs 320 + 145 + 42 + 58 + 22 + 33) and Rs 230 crore of capital expenditure (Rs 158 + 55 + 17), totalling Rs 850 crore. The Form 3CLA schedule attached to the return of income carries this Rs 850 crore into the tax computation as a Section 35(2AB) deduction (100 percent of eligible expenditure).

Filter four — the Ind AS 38 overlay — is a book-side control, not a tax adjustment. Assume that of the Rs 620 crore of revenue expenditure, Rs 180 crore relates to development-phase programmes (a specified biosimilar molecule and two specified generic molecules) that have crossed the Ind AS 38 six-condition threshold and are being capitalised as intangible assets in the books. The remaining Rs 440 crore of revenue expenditure is research-phase or does not meet the six-condition test and is expensed in the profit-or-loss account. On the capital side, all Rs 230 crore of laboratory equipment, instruments, and computers is capitalised under Ind AS 16 with depreciation charged over the asset’s useful life.

Under Ind AS 12, the timing differences are as follows. The Rs 180 crore book-capitalised development-phase intangible has a book carrying amount of Rs 180 crore at close but a tax written-down value of nil (revenue-expensed under Section 35(2AB)). The temporary difference is Rs 180 crore. At an applicable corporate tax rate of 25.17 percent (25 percent plus surcharge and cess for a domestic company not on Section 115BAA), the deferred tax liability recognised on this component is Rs 45.31 crore. On the capital side, the Rs 230 crore of laboratory equipment carries a book depreciation (Ind AS 16) that differs from tax depreciation under Section 32 (given the 100 percent Section 35(2AB) deduction on the acquisition-year capital, the tax base is nil going forward whereas the book carrying amount depreciates over the useful life). The additional DTL on this component is Rs 57.91 crore (25.17 percent times Rs 230 crore). Aggregate deferred tax liability arising from the Section 35(2AB) treatment for the previous year: Rs 103.22 crore, disclosed in the deferred-tax movement schedule of the notes to the financial statements and reconciling the current-tax and deferred-tax lines of the profit-and-loss account.

If the same company had elected into Section 115BAA at any prior year, the entire Section 35(2AB) column of this working paper would collapse — the DSIR approval would remain valid and Form 3CL would still be filed for regulatory record, but the return-side deduction and the associated deferred tax bridge would drop out of the tax computation. The strategic-plan decision on the Section 115BAA election therefore anchors whether the R&D reconciliation surface remains live for a given assessee.

Common reconciliation breakages

Five breakages recur across Indian pharma R&D reconciliation cycles and each maps to a specific control failure that a well-run finance function can eliminate ahead of the Form 3CL filing.

• Revenue-versus-capital misclassification at the R&D cost centre. The Form 3CL certificate splits the quantum by revenue and capital, and the split has real consequences downstream (the Ind AS 12 deferred tax base for capital items differs from the base for revenue items). A cost element booked to a revenue natural account in the general ledger but actually representing a piece of equipment installed at the facility must be reclassified on the working paper — and a cost element booked to a capital natural account that actually represents a consumable or a reagent must be reclassified in the other direction. Manual reconciliation typically leaves 2 to 4 percent of the quantum on the wrong side of the split; discipline requires a source-side tag on each cost element at the point of general-ledger posting rather than a reclassification at year-end.

• Building-refurbishment inclusion. Section 35(2AB) explicitly excludes cost of land and cost of any building. Building refurbishment on the R&D block — flooring, HVAC upgrades, cleanroom fit-out, false ceilings — is capitalised as building improvement under Ind AS 16 and does not qualify for Section 35(2AB) even though it is incurred at the approved facility and even though the R&D operations directly depend on it. Companies that include building refurbishment in the Form 3CL working paper create a permanent audit trail defect that will typically be picked up at the first DSIR review of the facility or at the first tax scrutiny after the year of claim.

• Marketed-product clinical trial cost. Clinical trials on marketed products conducted outside the approved facility are outside the Section 35(2AB) perimeter — DSIR’s position is that the marketed-product clinical trial is a post-launch cost of the pharmacovigilance and lifecycle management function and not a scientific research cost. Trials on new drugs conducted at the approved facility, or through a DSIR-approved contract research organisation up to the specified phase, are inside the perimeter. The classification discipline turns on the drug’s marketing status at the time of the trial and on the trial-site accreditation.

• Ind AS 38 development-phase call. The six-condition test is a judgement call that must be documented at the programme level with a date stamp and a written management position. Programmes that fail one or more conditions must remain in research phase and be expensed; programmes that pass all six may be capitalised. Companies that capitalise too aggressively (before technical feasibility is demonstrated) create an audit-adjustment risk with the statutory auditor. Companies that capitalise too conservatively (delaying capitalisation past the six-condition threshold date) understate the book carrying amount and mis-recognise the deferred tax movement. The reconciliation-failure-mode-analysis framework offers a structured cost-classification review that a large R&D finance function can layer onto the year-end close.

• Section 92BA specified-domestic-transaction slip. Where the DSIR-approved R&D centre transfers a molecule, a formulation, or an active pharmaceutical ingredient to a related formulation plant or licensing company within the same group, the transfer is a specified domestic transaction under Section 92BA and must carry Rule 10D transfer-pricing documentation supporting the arm’s-length price. Companies that treat the transfer as a book entry (at cost or at a nominal margin) without the SDT documentation create a scrutiny risk that surfaces two to three assessment years after the fact. The reconciliation-playbook framework carries the SDT trigger as a monthly-close control rather than a year-end reconciliation surface.

How a reconciliation platform handles this

A purpose-built pharma reconciliation platform ingests the R&D cost centre general ledger extract from the ERP, the fixed-asset register from the asset-management system, the Ind AS 38 development-phase capitalisation schedule from the finance function’s working papers, and the DSIR-listed-item taxonomy — and produces a per-facility Form 3CL preparation working paper that the statutory auditor can sample-test in a single working-paper cycle. The platform runs the DSIR-approved-facility gate on the plant code or cost centre hierarchy, applies the DSIR-listed-item filter against the cost element master, removes double-deducted items on the other-chapter flag, and produces the revenue-and-capital split at the granularity that the Form 3CL certificate expects. It then feeds the capital-side quantum into the deferred tax working paper alongside the Ind AS 38 development-phase intangible carrying amount, computes the Ind AS 12 DTL at the applicable corporate tax rate, and produces the deferred-tax movement schedule for the notes to the financial statements. Match rate improvement of 51 to 88 percent on the R&D cost centre to Form 3CL reconciliation, combined with an ISO 27001:2022 posture and DPDP Act 2023 aligned data handling, is what makes the platform an infrastructure investment for a large integrated pharma group with a multi-facility DSIR footprint rather than a manual working-paper substitute.

Cross-cluster bridges and where to read next

The Section 35(2AB) reconciliation anchors the tax-incentive perimeter for pharma R&D, but it interacts with several adjacent reconciliation surfaces that a large integrated pharma group closes in the same year-end cycle. For the eligibility carve-outs — the specific exclusions of land, building, marketed-product trials, and outsourced research — the deeper coverage sits in the Pharma R&D tax incentive Section 35(2AB) walkthrough. For the accounting treatment of USFDA remediation cost — a related book-tax reconciliation surface where Ind AS 37 provisions interact with Section 37 business-expense deductibility — read the USFDA Form 483 remediation cost accounting treatment guide. For the parallel incentive stack that runs on the manufacturing side rather than the R&D side, the PLI Pharma Rs 15,000 crore eligibility and incremental sales reconciliation walkthrough covers the base-year FY 2019-20 mechanics and the incremental-sales computation.

For the pharma GST cluster that runs alongside the income-tax cluster in the same close cycle — the 22 September 2025 rate rationalisation to 5 percent on all drugs and the transition mechanics — read GST Council 56 pharma drugs and medical devices 5 percent transition, the medical device HSN 9018-9022 rate change walkthrough, and the life-saving drugs nil-rate coverage. For the parallel inverted-duty refund mechanic that the pharma packaging chain shares with the dairy and edible-oil clusters, the dairy inverted-duty refund under Rule 89(5) post GST 2.0 cornerstone unpacks the Notification 14/2022 amended formula, and the edible oil Chapter 15 IDR refund blocked under Notification 09/2022 walkthrough covers the parallel blockage mechanic that also applies to Chapter 27 solvents in pharma API manufacture. The methodology anchor for the classification and cost-element reconciliation discipline sits in the reconciliation failure-mode analysis framework and the reconciliation playbook monthly close pillar. The commercial pillar for the entire pharma cluster is Pharma reconciliation software India; the broader authority is reconciliation software India.

The five FAQs below address the operational questions Indian pharma R&D controllers, tax leads, and statutory audit teams ask most often when preparing the year-end Form 3CL certificate, the Form 3CLA return schedule, and the associated Ind AS 12 deferred tax note.

Terra Insight Editorial Team Reconciliation Infrastructure

Content authored by practitioners with experience at Amazon India, Intuit QuickBooks, and the Tata Group. Meet the team →

Published 13 July 2026

Domain expertise

TDS Reconciliation GST Input Credit Platform Settlements NACH Batch Matching Bank Reconciliation Form 26AS Matching ERP Integrations Enterprise Finance Ops

Reviewed by

NK

Navin Krishnan

Managing Director & Founder — Terra Insight

Ex Amazon India · Intuit QuickBooks · Tata nexarc

ISO 27001:2022 Patent Pending Incorporated 2024